C1 inhibitor deficiency: 2014 United Kingdom consensus document

Clinical and Experimental Immunology

Volumn 180, Issue 3, 2015, Pages 475-483

  Longhurst, H J ^a   Tarzi, M D ^b   Ashworth, F ^c   Bethune, C ^d   Cale, C ^e   Dempster, J ^a   Gompels, M ^f   Jolles, S ^g   Seneviratne, S ^h   Symons, C ^d   Price, A ⁱ   Edgar, D ^j  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f NORTH BRISTOL NHS TRUST   (United Kingdom)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^h ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ Herditary Angioedema   (United Kingdom)

^j UK Primary Immunodeficiency Network (UK PIN)   (United Kingdom)

more..

Author keywords

C1 inhibitor deficiency; Guidelines; HAE; Hereditary angioedema

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR;

ANGIONEUROTIC EDEMA; ARTICLE; C1 INHIBITOR DEFICIENCY; CLINICAL IMMUNOLOGY; COMPLEMENT DEFICIENCY; CONSENSUS; CONSULTATION; DELPHI STUDY; HEALTH CARE PERSONNEL; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGIST; JOINT VENTURE; LIKERT SCALE; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RARE DISEASE; UNITED KINGDOM; ANGIOEDEMAS, HEREDITARY; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT;

ANGIOEDEMAS, HEREDITARY; DISEASE MANAGEMENT; HUMANS;

EID: 84929301166     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12584     Document Type: Article

References (50)

1. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012; 379:474-81.
2. Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev 2008; 8:156-9.
3. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94:498-503.
4. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009; 161:1153-8.
5. Jolles S, Williams P, Carne E et al. A UK national audit of hereditary and acquired angioedema. Clin Exp Immunol 2014; 175:59-67.
6. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71:206-15.
7. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75:349-54.
8. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130:692-7.
9. Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379-94.
10. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363:532-41.
11. Lumry WR, Li HH, Levy RJ et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107:529-37.
12. Zanichelli A, Bova M, Coerezza A, Petraroli A, Triggiani M, Cicardi M. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 2012; 67:1074-7.
13. Bas M, Greve J, Hoffmann TK et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013; 68:1452-9.
14. Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363:523-31.
15. Levy RJ, Lumry WR, McNeil DL et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104:523-9.
16. Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol 2011; 128:153-9 e4.
17. Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol 2013; 110:184-8 e2.
18. Craig TJ, Levy RJ, Wasserman RL et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124:801-8.
19. Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363:513-22.
20. Craig TJ, Bewtra AK, Hurewitz D et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc 2012; 33:354-61.
21. Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126:821-7 e14.
22. Riedl MA, Bernstein JA, Li H et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 2014; 112:163-9 e1.
23. Riedl MA, Levy RJ, Suez D et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 2013; 110:295-9.
24. Longhurst HJ, Farkas H, Craig T et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6:22.
25. Cicardi M, Craig TJ, Martinez-Saguer I, Hebert J, Longhurst HJ. Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013; 161 (Suppl. 1):3-9.
26. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19:147-51.
27. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117:904-8.
28. Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147:11-7.
29. Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012; 125:938 e1-7.
30. Bernstein JA. HAE update: epidemiology and burden of disease. Allergy Asthma Proc 2013; 34:3-6.
31. Nordenfelt P, Dawson S, Wahlgren CF, Lindfors A, Mallbris L, Bjorkander J. Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden. Allergy Asthma Proc 2014; 35:185-90.
32. Bouillet L, Launay D, Fain O et al. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol 2013; 111:290-4.
33. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31:407-14.
34. Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol 2013; 111:329-36.
35. Zuraw BL, Banerji A, Bernstein JA et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2013; 1:458-67.
36. Craig T, Aygoren-Pursun E, Bork K et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5:182-99.
37. Caballero T, Farkas H, Bouillet L et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129:308-20.
38. Bowen T, Cicardi M, Bork K et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008; 100:S30-40.
39. Cicardi M, Bork K, Caballero T et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67:147-57.
40. Bowen T, Cicardi M, Farkas H et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6:24.
41. Betschel S, Badiou J, Binkley K et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol 2014; 10:50. doi: 10.1186/1710-0000-0000-0000. eCollection 2014.
42. Transforming participation in health and care. Patients and Information Directorate, NHS England, Ref 00381. Available at: http://www.england.nhs.uk/wp-content/uploads/2013/09/trans-part-hc-guid1.pdf. Accessed March 10, 2015.
43. The UK strategy for rare diseases. Department of Health. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/260562/UK_Strategy_for_Rare_Diseases.pdf. Accessed March 10, 2015.
44. Manson AL, Price A, Dempster J et al. In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency. Clin Exp Immunol 2013; 173:1-7.
45. Clinical commissioning policy: treatment of acute attacks in hereditary angioedema. NHS Commissioning Board 2013. Available at: http://www.england.nhs.uk/wp-content/uploads/2013/04/b09-p-b.pdf. Accessed March 10, 2015.
46. UK PIN Accreditation Standards. Available at: http://www.ukpin.org.uk/home/accreditation-standards.html. Accessed March 10, 2015.
47. Saule CI, Boccon-Gibod O, Fain G et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy 2013; 4: 475-482.
48. Bygum A. Hereditary angioedema - consequences of a new treatment paradigm in Denmark. Acta Derm Venereol 2014; 94:436-441.
49. Grigoriadou S, Longhurst HJ. Clinical immunology review series: an approach to the patient with angio-oedema. Clin Exp Immunol 2009; 155:367-77.
50. Zuraw BL, Bork K, Binkley KE et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc 2012; 33 (Suppl 1):S145-56.